Knowing that the dosing elicits a downstream therapeutic change in the missing protein inside the target cells and that that "should, therefore, lead to correction of the disease process as a whole..." will give the PYC team great confidence, I would have thought. It certainly is a very positive flag for this shareholder!
Ann: PYC's Lead Drug Effective in Patient Derived Models Tested, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.050(4.35%) |
Mkt cap ! $673.6M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.20 | $1.13 | $208.6K | 177.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11081 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 6000 | 1 |
View Market Depth
| Last trade - 11.59am 23/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |